Abstract
Biological therapy for ankylosing spondylitis (AS) has led to improved disease control beyond that of conventional treatments. International recommendations encourage clinicians prescribing biological treatments to register patients in national registers to collect information on outcome and toxicity. Patients with AS (n = 229) from the Register of Biological Treatment in Finland (ROB-FIN) with severe disease of long duration were followed-up for up to 24 months. Due to an active disease, one or more concomitant disease-modifying antirheumatic drugs (DMARDs) were used by 86% at commencement of biological therapy. This add-on strategy with infliximab led to a rapid pain relief and improvement of patient’s and physician’s global assessments, C-reactive protein/erythrocyte sedimentation rate, and swollen and tender joint counts within 6 weeks. Concomitant use of NSAID and oral corticosteroid was reduced. Corresponding results were documented at 3 months with etanercept, which was more recently approved for the treatment of spondyloarthropathies. Seventy-nine percent of the patients were ASAS 20 responders. A subgroup of AS patients with only axial involvement (n = 46) responded correspondingly. The first biological drug was discontinued in only 7% due to lack of efficacy and in 6% due to adverse events. Anti-TNF agents, often used in combination with DMARDs, appeared to have persistent effectiveness and limited toxicity in a real-life clinical setting in a cohort of Finnish AS patients with severe disease and long disease duration.
Similar content being viewed by others
Notes
http://www.kaypahoito.fi, in Finnish
References
Braun J, Sieper J (2002) Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches. Arthritis Res 4:307–321
Boulos P, Dougados M, MacLeod SM et al (2005) Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs 65:2111–2127
Zochling J, Braun J (2005) Management and treatment of ankylosing spondylitis. Curr Opin Rheumatol 17:418–425
Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193
Davis JC Jr, van der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230–3236
Calin A, Dijkmans BAC, Emery P et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594–1600
Marzo-Ortega H, McGonagle D, Jarrett S et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64:1568–1575
van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582–591
Braun J, Pham T, Sieper J et al (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824
Braun J, Davis J, Dougados M et al (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65:316–320
Konttinen L, Honkanen V, Uotila T et al (2006) Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. Rheumatol Int 26:916–922
Konttinen L, Kankaanpaa E, Luosujarvi R et al (2006) Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 25:882–884
Nordstrom DC, Konttinen L, Korpela M et al (2006) Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Rheumatol Int26:741–748
Zochling J, Bohl-Bühler MHJ, Baraliakos X et al (2006) Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey. Clin Rheumatol 25:794–800
Breban M, Vignon E, Claudepierre P et al (2002) Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 41:1280–1285
Temekonidis TI, Alamanos Y, Nikas SN et al (2003) Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 62:1218–1220
Maksymowych WP, Jhangri GS, Lambert RG et al (2002) Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29:959–965
Braun J, Baraliakos X, Brandt J et al (2005) Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 34:178–190
Mottonen T, Hannonen P, Leirisalo-Repo M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 353:1568–1573
Wagner CL, Schantz A, Barnathan E et al (2003) Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol 112:37–53
Altan L, Bingol U, Karakoc Y et al (2001) Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 30:255–259
Roychowdhury B, Bintley-Bagot S, Bulgen DY et al (2002) Is methotrexate effective in ankylosing spondylitis? Rheumatology 41:1330–1332
Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M et al (2004) Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 31:1568–1574
Pham T, Landewe R, van der Linden S et al (2006) An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis 65:1620–1625
Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42:2325–2329
Keystone EC (2003) Advances in targeted therapy: safety of biological agents. Ann Rheum Dis 62:ii34–ii36
Haraoui B, Keystone E (2006) Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 18:96–100
Acknowledgements
The expert data processing and statistical assistance by Dr. Viljami Laine and secretarial assistance by Secretary Taina Käyhkö are greatly appreciated. This study has been supported by the Victoria Foundation, Finska Läkaresällskapet, the Perklen Foundation, the Juselius Foundation, the Center of Excellence of the Academy of Finland, and EVO projects. The ROB-FIN register has been financially supported by grants from Schering-Plough, Wyeth, Amgen, Abbott, and Biovitrum.
Author information
Authors and Affiliations
Corresponding author
Additional information
On behalf of the ROB-FIN Study Group
Rights and permissions
About this article
Cite this article
Konttinen, L., Tuompo, R., Uusitalo, T. et al. Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience. Clin Rheumatol 26, 1693–1700 (2007). https://doi.org/10.1007/s10067-007-0574-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-007-0574-5